Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure.
acute heart failure (AHF)
cardiorenal syndrome (CRS)
galectin-3 (Gal-3)
prognosis
renal function
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
01
2022
accepted:
14
03
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Galectin-3 (Gal-3) is an inflammatory marker associated with the development and progression of heart failure (HF). A close relationship between Gal-3 levels and renal function has been observed, but data on their interaction in patients with acute HF (AHF) are scarce. We aim to assess the prognostic relationship between renal function and Gal-3 during an AHF episode. This is an observational, prospective, multicenter registry of patients hospitalized for AHF. Patients were divided into two groups according to estimated glomerular filtration rate (eGFR): preserved renal function (eGFR ≥ 60 mL/min/1.73 m We included 1,201 patients in whom Gal-3 values were assessed at admission. The median value of Gal-3 in our population was 23.2 ng/mL (17.3-32.1). Gal-3 showed a negative correlation with eGFR (rho = -0.51; Gal-3 is a marker of high mortality in patients with acute HF and renal dysfunction. Renal function influences the prognostic value of Gal-3 levels, which should be adjusted by eGFR for a correct interpretation.
Identifiants
pubmed: 35463785
doi: 10.3389/fcvm.2022.861651
pmc: PMC9021836
doi:
Types de publication
Journal Article
Langues
eng
Pagination
861651Informations de copyright
Copyright © 2022 Caravaca Perez, González-Juanatey, Nuche, Matute-Blanco, Serrano, Martínez Selles, Vázquez García, Martínez Dolz, Gómez-Bueno, Pascual Figal, Crespo-Leiro, García-Osuna, Ordoñez-Llanos, Cinca Cuscullola, Guerra and Delgado.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2020 Dec 03;21(23):
pubmed: 33287402
Rev Esp Cardiol (Engl Ed). 2017 May;70(5):338-346
pubmed: 28011188
J Am Heart Assoc. 2012 Oct;1(5):e000760
pubmed: 23316284
J Am Heart Assoc. 2014 Sep 18;3(5):e000962
pubmed: 25237044
Int J Cardiol. 2014 Nov 15;177(1):171-7
pubmed: 25499371
Biomark Med. 2015;9(5):433-41
pubmed: 25985174
Heart Fail Clin. 2018 Jan;14(1):75-92
pubmed: 29153203
Circulation. 2018 Aug 28;138(9):929-944
pubmed: 30354446
Biomark Med. 2019 Jun;13(9):707-713
pubmed: 31157541
Acad Emerg Med. 2007 Jul;14(7):669-78
pubmed: 17595237
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Heart Fail. 2014 Jan;16(1):103-11
pubmed: 24453099
Circulation. 2004 Nov 9;110(19):3121-8
pubmed: 15520318
Adv Clin Exp Med. 2016 Jul-Aug;25(4):617-23
pubmed: 27629834
Eur J Heart Fail. 2010 Aug;12(8):826-32
pubmed: 20525986
Am J Pathol. 2008 Feb;172(2):288-98
pubmed: 18202187
BMC Cardiovasc Disord. 2016 May 31;16:117
pubmed: 27246703
J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24
pubmed: 16979009
Nat Rev Nephrol. 2016 Oct;12(10):610-23
pubmed: 27573728
JACC Heart Fail. 2015 Jan;3(1):59-67
pubmed: 25458174
Acad Emerg Med. 2007 Jul;14(7):662-8
pubmed: 17538078
Am J Nephrol. 2016;43(5):305-17
pubmed: 27166158
Circulation. 2019 Apr 16;139(16):e840-e878
pubmed: 30852913
Am J Pathol. 2000 Sep;157(3):815-23
pubmed: 10980121
Eur J Heart Fail. 2009 Sep;11(9):811-7
pubmed: 19648160